uniQure N.V. announced that 12 data presentations, including two oral presentations, will be delivered at the European Society of Gene and Cell Therapy (ESGCT) Annual Meeting being held October 24-27 in Brussels, Belgium. Specific details on uniQure's presentations taking place at ESGCT include: Invited Talk Title: Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntston's Disease. Presenter: Richard Porter, Chief Business and Scientific Officer, uniQure Session Title and Location: CNS & sensory diseases II, Session 10a, Shed 2A Date and Time: Friday, October 27, 8:30 a.m. GMT+2. Title: Gene therapy for C9ORF72-ALS reduces RNA toxicity and ameliorates behavioral phenotype in ALS mouse model.

Presenter: Vanessa Zancanella, Sr. Scientist Global Research, uniQure session Title and Location: CNS & Sensational diseases I, Session 2c, Maison de la Poste. Title: Pivotal safety studies for AMT-260, a novel AAV9-dual microRNA-based vector targeting GRIK2 for the treatment of temporal lobe epilepsy (Poster #433). Presenter: Nick Pearson, Sr. Director Toxicology & Translational Safety, Non-Clinical, uniQure Session Date and Time: Wednesday, 17:00 - 18:15, Thursday, 20:30 - 21:30 GMT+2. Title: Production of low cross-packaging AAV capsid libraries in insect cells (Poster #166).

Presenter: Bas Bosma, Scientific Leader, Technology Innovation, uniQure.